AR101225A1 - Vacunas de meningococos - Google Patents

Vacunas de meningococos

Info

Publication number
AR101225A1
AR101225A1 ARP150102269A ARP150102269A AR101225A1 AR 101225 A1 AR101225 A1 AR 101225A1 AR P150102269 A ARP150102269 A AR P150102269A AR P150102269 A ARP150102269 A AR P150102269A AR 101225 A1 AR101225 A1 AR 101225A1
Authority
AR
Argentina
Prior art keywords
meningocock
vaccines
polypeptide
meningococcal
composition
Prior art date
Application number
ARP150102269A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR101225A1 publication Critical patent/AR101225A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
ARP150102269A 2014-07-17 2015-07-16 Vacunas de meningococos AR101225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14177563 2014-07-17

Publications (1)

Publication Number Publication Date
AR101225A1 true AR101225A1 (es) 2016-11-30

Family

ID=51178811

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP150102269A AR101225A1 (es) 2014-07-17 2015-07-16 Vacunas de meningococos
ARP230102768A AR130778A2 (es) 2014-07-17 2023-10-17 Vacunas de meningococos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP230102768A AR130778A2 (es) 2014-07-17 2023-10-17 Vacunas de meningococos

Country Status (15)

Country Link
US (3) US11707513B2 (enExample)
EP (1) EP3169358A1 (enExample)
JP (2) JP6687597B2 (enExample)
KR (2) KR20230012100A (enExample)
CN (2) CN106659776A (enExample)
AR (2) AR101225A1 (enExample)
AU (2) AU2015289193A1 (enExample)
BE (1) BE1022878B1 (enExample)
BR (1) BR112017000519A2 (enExample)
CA (1) CA2954729C (enExample)
EA (1) EA038940B1 (enExample)
IL (1) IL249823B (enExample)
MX (1) MX2017000775A (enExample)
SG (2) SG10201900041VA (enExample)
WO (1) WO2016008961A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
MX2017000776A (es) 2014-07-17 2017-05-04 Glaxosmithkline Biologicals Sa Polipeptidos fhbp meningococicos modificados.
AU2015289193A1 (en) 2014-07-17 2017-02-02 Glaxosmithkline Biologicals S.A. Meningococcus vaccines
US10975131B2 (en) * 2015-10-27 2021-04-13 University Of Massachusetts Factor H-Fc immunotheraphy
CN107961369B (zh) * 2017-03-22 2020-08-11 武汉博沃生物科技有限公司 多价脑膜炎球菌缀合疫苗及其制备方法
CN108939061A (zh) * 2018-08-03 2018-12-07 北京智飞绿竹生物制药有限公司 一种多组分b群脑膜炎球菌疫苗及其制备方法
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US11014736B2 (en) 2019-04-18 2021-05-25 Altria Client Services Llc Sliding packs with flip top hinged lids
CN110804101A (zh) * 2019-11-08 2020-02-18 苏州微超生物科技有限公司 B群脑膜炎球菌相关融合蛋白、疫苗及其制备方法与应用
MX2022006299A (es) * 2019-11-25 2023-01-19 Univ Griffith Proteína inmunogénica contra una infección gonocócica.
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
CN119792505A (zh) * 2023-10-10 2025-04-11 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
ES2588917T3 (es) * 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
EP2544714A1 (en) * 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
TR201802933T4 (tr) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201120634D0 (en) 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
ES2847923T3 (es) * 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
EP2916512B1 (en) 2014-03-07 2016-08-24 Mitsubishi Electric R&D Centre Europe B.V. Method for classifying a TCP connection carrying HTTP traffic as a trusted or an untrusted TCP connection
MX2017000776A (es) 2014-07-17 2017-05-04 Glaxosmithkline Biologicals Sa Polipeptidos fhbp meningococicos modificados.
AU2015289193A1 (en) 2014-07-17 2017-02-02 Glaxosmithkline Biologicals S.A. Meningococcus vaccines
MX2021000081A (es) 2018-06-21 2021-03-25 Basf Se Derivados de difosfato de 3-fenil-benzofuran-2-ona como estabilizantes.

Also Published As

Publication number Publication date
CN106659776A (zh) 2017-05-10
IL249823B (en) 2022-07-01
JP6687597B2 (ja) 2020-04-22
US12485164B2 (en) 2025-12-02
AU2019201131B2 (en) 2020-08-27
BE1022878B1 (fr) 2016-09-30
JP2017522319A (ja) 2017-08-10
IL249823A0 (en) 2017-03-30
AR130778A2 (es) 2025-01-15
BR112017000519A2 (pt) 2017-11-21
BE1022878A1 (fr) 2016-09-30
KR20230012100A (ko) 2023-01-25
SG11201610946YA (en) 2017-01-27
CN113827712A (zh) 2021-12-24
JP2020117523A (ja) 2020-08-06
EP3169358A1 (en) 2017-05-24
WO2016008961A1 (en) 2016-01-21
EA201692554A1 (ru) 2017-07-31
EA038940B1 (ru) 2021-11-12
AU2015289193A1 (en) 2017-02-02
KR102626831B1 (ko) 2024-01-22
CA2954729C (en) 2023-08-22
US11707513B2 (en) 2023-07-25
US20260097107A1 (en) 2026-04-09
AU2019201131C1 (en) 2021-03-18
JP7074793B2 (ja) 2022-05-24
MX2017000775A (es) 2017-05-04
CA2954729A1 (en) 2016-01-21
SG10201900041VA (en) 2019-02-27
KR20170029615A (ko) 2017-03-15
US20180214531A1 (en) 2018-08-02
AU2019201131A1 (en) 2019-03-07
US20230414736A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
AR130778A2 (es) Vacunas de meningococos
ES2659418T3 (es) Una estructura de transferencia, un sistema de transferencia y un método para la transferencia de GNL y/o energía eléctrica
MX2016014564A (es) Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido.
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
CY1123622T1 (el) Τροποποιημενα μηνιγγιτιδοκοκκικα fhbp πολυπεπτιδια
PL3142858T3 (pl) Przepuszczająca powietrze i mikroporowata cienka termoplastyczna membrana
EP3119424A4 (en) Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
EP3145689A4 (en) Layerless bioprinting via dynamic optical projection and uses thereof
BR112017007466A2 (pt) métodos para preparar uma composição seca e reconstituir uma composição seca, pasta, composição seca, recipiente, kit homeostático, e, seringa.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
MY193650A (en) Extracellular matrix compositions
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EP3153794A4 (en) Cooling device, light source device provided with cooling device, and projection-type image display device provided with light source device
CL2016002223A1 (es) Microorganismo recombinante que expresa análogos de avermectina y uso de los mismos.
ZA201805159B (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
CL2016001746A1 (es) Derivados de hidroxi formamida y sus usos
PE20161197A1 (es) Sistemas y metodos para reparar membranas y mejorar el rendimiento de los sistemas de membranas impulsados osmoticamente
MX2020004133A (es) Oligosacaridos inmunomoduladores.
BR112016022787A2 (pt) método para induzir uma resposta imune em um indivíduo humano, composição imunogênica, e, uso de uma segunda composição imunogênica
MX2017000076A (es) Macromoleculas estrellas compatibles con tensoactivos.
MX371128B (es) Compuestos de dihidropirimidin-2-ona y su uso medico.
UY35545A (es) Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación
CL2018000513A1 (es) Vacunas de pestivirus para temblores congénitos
EP3187249A4 (en) Hollow fiber membrane and hollow fiber membrane module
CL2016001801A1 (es) Proceso para la reconstitución de una forma sólida de una composición farmacéutica.

Legal Events

Date Code Title Description
FC Refusal